rLP2086 vaccine

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

Meningitis, MeningococcalMeningococcal B Disease

Phase 2

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

CompletedNCT02534935

PfizerMeningococcal B Disease

Start: 2015-08-31End: 2020-03-17Updated: 2021-09-27

Phase 3

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

CompletedNCT01352793

PfizerMeningitis, Meningococcal

Start: 2012-11-30End: 2014-09-30Updated: 2015-03-11

Related Papers

Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.

2022-09-077 citations

Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.

2022-02-112 citations